
Introducing drug-anti-body conjugates
Loading player...
Dr Lizanne Langenhoven details how knowing the subtype of breast cancer determines treatment, and introduces the new drug-antibody conjugates for HER2-positive breast cancer.
Dr Lizanne Langenhoven is a clinical and radiation oncologist at Panorama Mediclinic and forms part of a multi-disciplinary unit of excellence in the treatment of breast cancer at the Panorama Centre for Surgical Oncology.
Dr Lizanne Langenhoven is a clinical and radiation oncologist at Panorama Mediclinic and forms part of a multi-disciplinary unit of excellence in the treatment of breast cancer at the Panorama Centre for Surgical Oncology.